Drug Approval | November 09, 2024
Lupin receives tentative approval from USFDA for Raltegravir Tablets
This product will be manufactured at Lupin’s Nagpur facility in India
This product will be manufactured at Lupin’s Nagpur facility in India
Emcure Pharmaceuticals has reported total income of Rs. 2,037.63 crores during the period ended September 30, 2024
The company has reported total income of Rs. 1,693.15 crores during the period ended September 30, 2024
Neuland Laboratories has reported total income of Rs. 315.17 crores during the period ended September 30, 2024
Max Healthcare Institute has reported total income of Rs. 1,748.30 crores during the period ended September 30, 2024
Apollo Hospitals Enterprise has reported total income of Rs. 5,627.5 crores during the period ended September 30, 2024
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
Subscribe To Our Newsletter & Stay Updated
